ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23% Market Closed
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Pre-Tax Income
-$28.5m
CAGR 3-Years
8%
CAGR 5-Years
-18%
CAGR 10-Years
-32%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Pre-Tax Income
-CA$7.4m
CAGR 3-Years
-149%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Pre-Tax Income
-$2.1m
CAGR 3-Years
57%
CAGR 5-Years
21%
CAGR 10-Years
13%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Pre-Tax Income
-$20.1m
CAGR 3-Years
49%
CAGR 5-Years
20%
CAGR 10-Years
-3%
Covalon Technologies Ltd
XTSX:COV
Pre-Tax Income
-CA$823.4k
CAGR 3-Years
52%
CAGR 5-Years
33%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Pre-Tax Income
-CA$25.1m
CAGR 3-Years
-44%
CAGR 5-Years
-53%
CAGR 10-Years
-8%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.86 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Pre-Tax Income?
Pre-Tax Income
-28.5m USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Pre-Tax Income amounts to -28.5m USD.

What is ESSA Pharma Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-32%

Over the last year, the Pre-Tax Income growth was -7%. The average annual Pre-Tax Income growth rates for ESSA Pharma Inc have been 8% over the past three years , -18% over the past five years , and -32% over the past ten years .

Back to Top